ifosfamide has been researched along with nintedanib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bovée, JVMG; Brahmi, M; Charon-Barra, C; Cousin, S; de Haan, J; De Meulemeester, L; Domènech, M; Dudzisz-Śledź, M; Estival, A; Gelderblom, H; Karavasilis, V; Litière, S; Marquina, G; Marreaud, S; Olungu, C; Schöffski, P; Steeghs, N; Toulmonde, M; Wozniak, A | 1 |
1 trial(s) available for ifosfamide and nintedanib
Article | Year |
---|---|
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-
Topics: Adult; Aged; Female; Humans; Ifosfamide; Indoles; Male; Medical Futility; Middle Aged; Neoplasm Staging; Progression-Free Survival; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Sarcoma | 2021 |